(Q36055449)

11 August 2017

1 reference

title

An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists (English)

1 reference

11 August 2017

0 references

1 reference

Dean A Regier

2

0 references

Alan Brennan

object named as

Alan Brennan

4

0 references

Nick Bansback

object named as

Nick J Bansback

1

0 references

author name string

Roberta Ara

3

1 reference

11 August 2017

Kamran Shojania

5

1 reference

11 August 2017

John M Esdaile

6

1 reference

11 August 2017

Aslam H Anis

7

1 reference

11 August 2017

Carlo A Marra

8

1 reference

11 August 2017

1 January 2005

1 reference

11 August 2017

1 reference

11 August 2017

65

1 reference

11 August 2017

4

1 reference

11 August 2017

473-496

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200565040-00004

11 August 2017

0 references

cites work

Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study

1 reference

12 December 2020

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

12 December 2020

Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

1 reference

12 December 2020

The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis.

1 reference

12 December 2020

Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials

1 reference

12 December 2020

Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)

1 reference

12 December 2020

Association of mortality with disease severity in rheumatoid arthritis, independent of comorbidity

1 reference

12 December 2020

Functional impairment and disability in early rheumatoid arthritis--development over 5 years

1 reference

12 December 2020

1 reference

12 December 2020

The costs of rheumatoid arthritis: an international long-term view

1 reference

12 December 2020

A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.

1 reference

12 December 2020

The responsiveness of generic health status measures as assessed in patients with rheumatoid arthritis receiving infliximab

1 reference

12 December 2020

Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case.

1 reference

12 December 2020

Guidelines for the management of rheumatoid arthritis: 2002 Update

1 reference

12 December 2020

Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

1 reference

12 December 2020

Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone

1 reference

12 December 2020

The friction cost method for measuring indirect costs of disease.

1 reference

12 December 2020

The costs of rheumatoid arthritis. a patient-oriented study of chronic disease costs

1 reference

12 December 2020

Association between etanercept use and employment outcomes among patients with rheumatoid arthritis

1 reference

12 December 2020

Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage

1 reference

12 December 2020

A comparative review of four preference-weighted measures of health-related quality of life

1 reference

12 December 2020

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

12 December 2020

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

12 December 2020

Rating of arthritis health states by patients, physicians, and the general public. Implications for cost-utility analyses.

1 reference

12 December 2020

Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel.

1 reference

12 December 2020

Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group

1 reference

12 December 2020

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

1 reference

12 December 2020

The lifetime economic costs of rheumatoid arthritis

1 reference

12 December 2020

Variation in the estimation of quality-adjusted life-years by different preference-based instruments

1 reference

12 December 2020

TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden

1 reference

12 December 2020

Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.

1 reference

12 December 2020

Rational use of new and existing disease-modifying agents in rheumatoid arthritis

1 reference

12 December 2020

Do rheumatology cost-effectiveness analyses make sense?

1 reference

12 December 2020

Adaptation and validation of the rheumatoid arthritis quality of life scale for use in Canada.

1 reference

12 December 2020

A retrospective analysis of the effect of noncompliance on time to first major adverse cardiac event in LIPS.

1 reference

12 December 2020

The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis

1 reference

12 December 2020

A comparison of the EuroQol-5D and the Health Utilities Index mark 3 in patients with rheumatic disease

1 reference

12 December 2020

An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline

1 reference

12 December 2020

Economic burden of rheumatoid arthritis: a systematic review

1 reference

12 December 2020

The 'side effects' of rheumatoid arthritis: joint destruction, disability and early mortality

1 reference

12 December 2020

Preference-based measures in economic evaluation in health care

1 reference

12 December 2020

ARAMIS today: moving toward internationally distributed databank systems for follow-up studies.

1 reference

12 December 2020

A comparison of the Assessment of Quality of Life (AQoL) with four other generic utility instruments

1 reference

12 December 2020

Long-term morbidity, mortality, and economics of rheumatoid arthritis

1 reference

12 December 2020

A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis

1 reference

12 December 2020

Costs and outcomes in rheumatoid arthritis and osteoarthritis

1 reference

12 December 2020

The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation.

1 reference

12 December 2020

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

1 reference

12 December 2020

Predicting mortality in patients with rheumatoid arthritis

1 reference

12 December 2020

Measuring the effects of medication use on health-related quality of life in patients with rheumatoid arthritis. A review

1 reference

12 December 2020

Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies

1 reference

12 December 2020

Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D).

1 reference

12 December 2020

Cardiovascular mortality in patients with rheumatoid arthritis

1 reference

12 December 2020

Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study

1 reference

12 December 2020

Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs

1 reference

12 December 2020

A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings

1 reference

12 December 2020

Assessment of quality of life in rheumatoid arthritis: methods and implications

1 reference

12 December 2020

Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method.

1 reference

12 December 2020

Responsiveness of health status measures and utility-based methods in patients with rheumatoid arthritis.

1 reference

12 December 2020

How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS)

1 reference

12 December 2020

Infliximab treatment of rheumatoid arthritis and Crohn's disease

1 reference

12 December 2020

Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis

1 reference

12 December 2020

The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Data Work Groups.

1 reference

12 December 2020

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

12 December 2020

Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years

1 reference

12 December 2020

The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation for Managed Care Pharmacy Task Force report

1 reference

12 December 2020

Rheumatoid arthritis and the risk of malignancy

1 reference

12 December 2020

Re: Wolfe et al. Do rheumatology cost-effectiveness analyses make sense?

1 reference

12 December 2020

Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years

1 reference

12 December 2020

Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis

1 reference

12 December 2020

A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis.

1 reference

12 December 2020

Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis.

1 reference

12 December 2020

The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument.

1 reference

12 December 2020

Cost of disease and illness in the United States in the year 2000

1 reference

12 December 2020

A review of cost-effectiveness analyses in rheumatology and related disciplines

1 reference

12 December 2020

Economic consequences of the progression of rheumatoid arthritis in Sweden

1 reference

12 December 2020

The burden of rheumatoid arthritis: facts and figures.

1 reference

12 December 2020

One thousand health-related quality-of-life estimates

1 reference

12 December 2020

Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study.

1 reference

12 December 2020

Regression to the mean: a potential source of error in clinical pharmacological studies

1 reference

12 December 2020

Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period

1 reference

12 December 2020

Responsiveness of the core set, response criteria, and utilities in early rheumatoid arthritis

1 reference

12 December 2020

Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study

1 reference

12 December 2020

Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria

1 reference

12 December 2020

The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study

1 reference

12 December 2020

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.

1 reference

12 December 2020

Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost

1 reference

12 December 2020

Locomotion status and costs in destructive rheumatoid arthritis. A comprehensive study of 82 patients from a population of 13,000

1 reference

12 December 2020

Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: analysis of 122 studies

1 reference

12 December 2020

Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate

1 reference

12 December 2020

Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration

1 reference

12 December 2020

Value of the time trade off method for measuring utilities in patients with rheumatoid arthritis

1 reference

12 December 2020

Development of a disease activity score based on judgment in clinical practice by rheumatologists.

1 reference

12 December 2020

Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK.

1 reference

12 December 2020

10.2165/00003495-200565040-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

11 August 2017

0 references

1 reference